Nevertheless, the applicability of these approaches might be limited because of the widespread expression of FAP, especially in bone marrow and muscle, and systemic targeting of FAP+ cells might result in cachexia, bone toxicity, muscle loss, or even death.121. The gene discussed is FAP; the disease is Cachexia.